Promising combo targets tough leukemia in vulnerable patients

This study is testing whether a combination of three drugs—venetoclax, a hypomethylating agent (azacitidine or decitabine), and low-dose cytarabine—can effectively treat adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated AML) who are not healthy enough for intensive chemotherapy. The 29 participants will receive two cycles of induction therapy, and those who respond well will continue with at least four more cycles. Researchers will track how long patients stay cancer-free, their remission rates, and side effects.